TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00189488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an intravenous (IV) bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conditioning Regimen
Description: Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant
Description: Allogeneic marrow/peripheral blood progenitor cell transplantation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic stem cell transplant
Description: Allogeneic marrow/peripheral blood progenitor cell transplantation
Study: NCT03694405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-DT
Description: Booster vaccination with MenACWY-DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-DT
Description: Booster vaccination with MenACWY-DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Description: Booster vaccination with MenACWY-TT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Description: Booster vaccination with MenACWY-TT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Description: Booster vaccination with MenACWY-TT
Study: NCT02204930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PeproStat
Description: A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
Study: NCT03382886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity
Study: NCT00725777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: Standard artemether-lumefantrine treatment
Study: NCT01026012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
Study: NCT01342913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100mcg/Vilanterol 25mcg
Description: Inhalation Powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticaosne Propionate 500mcg/Salmeterol 50mcg
Description: Inhalation Powder
Study: NCT02426333

Intervention type: OTHER
Intervention: Abiraterone Acetate
Description: Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
Study: NCT00923923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress
Description: compare levels of stress
Study: NCT02869633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04024891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1%
Description: 1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Topical Sterile Ophthalmic Solution
Study: NCT00189488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study: NCT01772446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS MESSAGING
Description: SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
Study: NCT01764685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Max therapeutic dose of 150mg/day

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
Study: NCT04098523

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex ultrasound
Description: A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
Study: NCT00359463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag
Description: Subjects will be administered a single oral dose of 50 mg eltrombopag.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Subjects will be administered a single oral dose of 50 mg eltrombopag.
Study: NCT01764685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01015339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 infusion,d1,d8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Study: NCT01494948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: allergen challenge
Description: nasal challenges with antigen to which they are sensitive to

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: allergen challenge
Description: nasal challenges with antigen to which they are sensitive to
Study: NCT04149249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention Video Doctor
Description: Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention no Video Doctor
Description: Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
Study: NCT02018341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic remedy in 30C potency
Study: NCT01015339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 80mg/m2, day 1 of every 3 weeks
Study: NCT04029194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistance with old age pension application
Description: The intervention will offer elderly assistance in applying for the old age pension.
Study: NCT04362384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E ovules
Description: Endoanal vitamin E ovules will be prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone ointment
Description: Endoanal Prednisolone ointment will be prescribed
Study: NCT02717351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-07)
Study: NCT01262677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 165 mg, once per day (QD) for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 165 mg, once per day (QD) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched to the active drug
Study: NCT03805347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helminthostachys zeylanica(L.)Hook
Description: Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Starch in capsule, 1gm/time, 3 times daily
Study: NCT02018341

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01772966

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal manipulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Study: NCT00972101

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 3 Gy of radiation on Days -7,-6, -5 and -4.
Study: NCT00847925

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later
Study: NCT04057066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
Study: NCT04513756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach
Description: Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
Study: NCT03973359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygienic recommendations
Description: Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
Study: NCT03450863

Intervention type: DRUG
Intervention: Fast-acting insulin aspart
Description: Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
Study: NCT01050634

Intervention type: DRUG
Intervention: Aromasin (exemestane)
Description: 25mg oral tablet, daily, for \>1yr
Study: NCT00900510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision and drainage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/Sulfamethoxazole (Bactrim)
Description: Trimethoprim/Sulfamethoxazole, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02587520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1
Description: 0.5 milliliter (mL), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1
Description: 0.5 milliliter (mL), Intramuscular
Study: NCT00847925

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later

Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later
Study: NCT04258501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry fruit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry leaf

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bean

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry
Study: NCT02587520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1
Description: 0.5 milliliter (mL), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, Intramuscular
Study: NCT04258501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turmeric

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turmeric
Study: NCT02587520

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT02730728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20ml bolus of 0.5% ropivicaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Ropivicaine at 8 milliliter/hour
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Ropivicaine at 8 milliliter/hour
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5ml bolus of 0.5% ropivicaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5ml bolus of 0.5% ropivicaine
Description: Local anesthetic
Study: NCT01865266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinaststin for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinaststin for injection
Study: NCT04258501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turmeric

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice porridge
Study: NCT02863497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Sex Therapy
Description: These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
Study: NCT01865266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02875535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLAS
Description: The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide).
Study: NCT03623243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siponimod
Description: Siponimod 2mg tablets taken once daily
Study: NCT02572544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)
Description: Wearing multiple and single pinhole glasses